$ONC

Wu Xiaobin sold $164K of ONC

Wu Xiaobin (President and COO) sold 626 shares of BeOne Medicines Ltd. (ONC) at $261.20 ($0.16M total) on 2026-06-11.

Original reporting
SEC EDGAR · Wu Xiaobin
Published Jun 15, 2026, 9:55 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 15, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ONC
Neutral
high confidence
Mentioned
$ONC
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ONCNeutralLow
01

Why it matters

This adds a fresh, timestamped data point on insider ownership but does not include new clinical, regulatory, financial, or deal information that would typically reprice the stock.

02

Market read

Traders may monitor insider activity as a sentiment input, but the filing alone is unlikely to drive a material repricing without other catalysts.

03

What to watch

The article notes no pre-arranged 10b5-1 plan, which can increase interpretive uncertainty, but the disclosure still lacks any fundamental linkage.

Relevance 4/10Novelty 8/10Timing: Filed 2026-06-15 (transaction dated 2026-06-11)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for BeOne Medicines Ltd. (ONC).

Company-level read

Ticker impact

$ONCNeutralHigh confidence
Context

SEC Form 4 shows ONC President/COO Wu Xiaobin sold 626 shares in an open-market transaction on 2026-06-11 at $261.2017.

Expected impact

Likely minimal near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider sale with no 10b5-1 plan stated and no accompanying operational/regulatory catalyst in the text.

Market effects

No sector read-across provided; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification/taxes rather than bearish expectations, especially for small share counts.

Key entities

  • BeOne Medicines Ltd.

    Subject of the Form 4 insider transaction disclosure.

  • Wu Xiaobin

    President and COO who sold 626 shares of ONC.

Related articles

$ONCHigh

BeOne Medicines Ltd. (ONC): Results of Operations and Financial Condition

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exhibit991-q22026earningsr.htm EX-99.1 Document Exhibit 99.1 BeOne Medicines Announces Second Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.7 billion for the second quarter, an increase of 30% from the prior year • BRUKINSA (zanubruti

$CRCLMed

Here Are Monday’s Best Wall Street Analyst Research Calls: Atmos Energy, Best Buy, Biogen, Capital One, Costco, Disney, Papa John’s International, Shopify, and More

The article lists Monday analyst calls and market moves. It highlights SK hynix’s Nasdaq debut, up about 12.8% to $168.01 after raising nearly $26.5B. It cites upgrades including BIIB to Buy at $235, COF to Buy at $229, and SHOP to Buy at $160, plus downgrades like BBY to Hold. Circle (CRCL) rose ~15% on OCC approval.

$ONCMed

BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline

Citizens kept a “Market Outperform” rating and $396 price target on BeOne Medicines (NASDAQ:ONC) after the company presented tumor clinical data at ASCO 2026. Citizens highlighted three pipeline programs: BGB-43395 (HR+/HER2- metastatic breast cancer), BG-C9074 (ovarian cancer maintenance), and BGB-B2033 (liver cancer). The target was based on discounted earnings and revenue multiples, with Citizens citing $4.85 billion cash and 88% gross margins.